Israeli GSF To Charge Formulary Request Fees

26 February 1996

Israel's General Sick Fund has told pharmaceutical suppliers that it will now charge NIS10,000 ($3,190) for a request to include a new drug on its formulary. The Fund receives 20-25 such requests a year, and approves about 15.

A GSF spokesman said the fee will cover some expenses related to handling applications, eg literature and database searches, obtaining professional opinions and specialist committee meetings. Also, the GSF has agreed to industry's long-standing request to make direct applications. Previously, the initiative for most applications had to come from a GSF doctor, usually working in a GSF hospital. The fee would not cover generic versions of listed products, or product extensions.

Importers Refuse To Pay Most new products are launched by local units of multinational firms. Their organization, the Pharmaceutical Importers' Section of the Chamber of Commerce, has written to the GSF expressing "amazement" at the fee arrangement, asking it to reconsider its decision and saying its members will not pay the fee.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight